Past Events
November 10, 2022

Poster: “A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors”
Number: 1475

April 13, 2022 at 2:00 PM CEST
Registered Office of Molecular Partners AG
Wagistrasse 14,
8952 Schlieren,